Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial

医学 类风湿性关节炎 安慰剂 内科学 痹症科 临床终点 类风湿因子 物理疗法 临床试验 阿巴塔克普 关节炎 替代医学 病理 淋巴瘤 美罗华
作者
Andrew P. Cope,Marianna Jasenecova,Joana C. Vasconcelos,Andrew Filer,Karim Raza,Sumera Qureshi,Maria Antonietta D’Agostino,Iain B. McInnes,John D. Isaacs,Arthur G. Pratt,Benjamin A. Fisher,Christopher D. Buckley,Paul Emery,Pauline Ho,Maya H Buch,Coziana Ciurtin,Dirkjan van Schaardenburg,T. Huizinga,René E. M. Toes,Evangelos Georgiou
出处
期刊:The Lancet [Elsevier BV]
卷期号:403 (10429): 838-849 被引量:72
标识
DOI:10.1016/s0140-6736(23)02649-1
摘要

BackgroundIndividuals with serum antibodies to citrullinated protein antigens (ACPA), rheumatoid factor, and symptoms, such as inflammatory joint pain, are at high risk of developing rheumatoid arthritis. In the arthritis prevention in the pre-clinical phase of rheumatoid arthritis with abatacept (APIPPRA) trial, we aimed to evaluate the feasibility, efficacy, and acceptability of treating high risk individuals with the T-cell co-stimulation modulator abatacept.MethodsThe APIPPRA study was a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial done in 28 hospital-based early arthritis clinics in the UK and three in the Netherlands. Participants (aged ≥18 years) at risk of rheumatoid arthritis positive for ACPA and rheumatoid factor with inflammatory joint pain were recruited. Exclusion criteria included previous episodes of clinical synovitis and previous use of corticosteroids or disease-modifying antirheumatic drugs. Participants were randomly assigned (1:1) using a computer-generated permuted block randomisation (block sizes of 2 and 4) stratified by sex, smoking, and country, to 125 mg abatacept subcutaneous injections weekly or placebo for 12 months, and then followed up for 12 months. Masking was achieved by providing four kits (identical in appearance and packaging) with pre-filled syringes with coded labels of abatacept or placebo every 3 months. The primary endpoint was the time to development of clinical synovitis in three or more joints or rheumatoid arthritis according to American College of Rheumatology and European Alliance of Associations for Rheumatology 2010 criteria, whichever was met first. Synovitis was confirmed by ultrasonography. Follow-up was completed on Jan 13, 2021. All participants meeting the intention-to-treat principle were included in the analysis. This trial was registered with EudraCT (2013–003413–18).FindingsBetween Dec 22, 2014, and Jan 14, 2019, 280 individuals were evaluated for eligibility and, of 213 participants, 110 were randomly assigned to abatacept and 103 to placebo. During the treatment period, seven (6%) of 110 participants in the abatacept group and 30 (29%) of 103 participants in the placebo group met the primary endpoint. At 24 months, 27 (25%) of 110 participants in the abatacept group had progressed to rheumatoid arthritis, compared with 38 (37%) of 103 in the placebo group. The estimated proportion of participants remaining arthritis-free at 12 months was 92·8% (SE 2·6) in the abatacept group and 69·2% (4·7) in the placebo group. Kaplan–Meier arthritis-free survival plots over 24 months favoured abatacept (log-rank test p=0·044). The difference in restricted mean survival time between groups was 53 days (95% CI 28–78; p<0·0001) at 12 months and 99 days (95% CI 38–161; p=0·0016) at 24 months in favour of abatacept. During treatment, abatacept was associated with improvements in pain scores, functional wellbeing, and quality-of-life measurements, as well as low scores of subclinical synovitis by ultrasonography, compared with placebo. However, the effects were not sustained at 24 months. Seven serious adverse events occurred in the abatacept group and 11 in the placebo group, including one death in each group deemed unrelated to treatment.InterpretationTherapeutic intervention during the at-risk phase of rheumatoid arthritis is feasible, with acceptable safety profiles. T-cell co-stimulation modulation with abatacept for 12 months reduces progression to rheumatoid arthritis, with evidence of sustained efficacy beyond the treatment period, and with no new safety signals.FundingBristol Myers Squibb.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
闾丘剑封发布了新的文献求助10
刚刚
可爱的函函应助小晓采纳,获得10
3秒前
Owen应助SciEngineerX采纳,获得10
3秒前
幸福大白发布了新的文献求助30
4秒前
内向寒云完成签到,获得积分10
6秒前
CipherSage应助DC采纳,获得10
6秒前
淡然的花卷完成签到,获得积分10
7秒前
9秒前
无语的不言完成签到,获得积分20
10秒前
10秒前
慕青应助lzx采纳,获得10
11秒前
11秒前
11秒前
Orange应助欧耶采纳,获得10
12秒前
12秒前
12秒前
yyyyyyy完成签到,获得积分10
14秒前
SciEngineerX发布了新的文献求助10
15秒前
木木完成签到,获得积分10
15秒前
啧啧啧发布了新的文献求助10
16秒前
研友_VZG7GZ应助33采纳,获得30
16秒前
yyyyyyy发布了新的文献求助10
17秒前
17秒前
禹代秋发布了新的文献求助10
18秒前
杰2580发布了新的文献求助10
19秒前
20秒前
20秒前
幸福大白发布了新的文献求助30
20秒前
量子星尘发布了新的文献求助10
21秒前
禹代秋完成签到,获得积分10
21秒前
LAVINE完成签到 ,获得积分10
22秒前
欧耶发布了新的文献求助10
24秒前
啧啧啧完成签到,获得积分10
25秒前
高手中的糕手完成签到,获得积分10
27秒前
gsj发布了新的文献求助10
32秒前
优雅翎完成签到,获得积分10
33秒前
喜喵喵发布了新的文献求助10
34秒前
35秒前
清脆凡阳发布了新的文献求助10
35秒前
张雯思给张雯思的求助进行了留言
36秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989450
求助须知:如何正确求助?哪些是违规求助? 3531621
关于积分的说明 11254315
捐赠科研通 3270207
什么是DOI,文献DOI怎么找? 1804928
邀请新用户注册赠送积分活动 882105
科研通“疑难数据库(出版商)”最低求助积分说明 809176